---
title: "Chardan Capital Sticks to Their Buy Rating for ZOOZ Strategy Ltd (ZOOZ)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280935181.md"
description: "Chardan Capital analyst James McIlree has maintained a Buy rating for ZOOZ Strategy Ltd (ZOOZ) with a price target of $2.00. The current analyst consensus for ZOOZ is a Moderate Buy, also with an average price target of $2.00. McIlree has an average return of -28.5% and a success rate of 22.97% according to TipRanks."
datetime: "2026-03-30T01:15:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280935181.md)
  - [en](https://longbridge.com/en/news/280935181.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280935181.md)
---

# Chardan Capital Sticks to Their Buy Rating for ZOOZ Strategy Ltd (ZOOZ)

Chardan Capital analyst James McIlree reiterated a Buy rating on ZOOZ Strategy Ltd yesterday and set a price target of $2.00.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, McIlree is an analyst with an average return of \-28.5% and a 22.97% success rate.

Currently, the analyst consensus on ZOOZ Strategy Ltd is a Moderate Buy with an average price target of $2.00.

### Related Stocks

- [ZOOZW.US](https://longbridge.com/en/quote/ZOOZW.US.md)
- [ZOOZ.US](https://longbridge.com/en/quote/ZOOZ.US.md)

## Related News & Research

- [Strategy CEO Phong Le thinks MSTR stock will outperform Bitcoin during the next bull market. Here's why he's wrong.](https://longbridge.com/en/news/296023440.md)
- [Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical Strategy](https://longbridge.com/en/news/295521208.md)
- [Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts](https://longbridge.com/en/news/295889108.md)
- [Cantor Fitzgerald Reaffirms Their Buy Rating on Hyperion DeFi (HYPD)](https://longbridge.com/en/news/295800453.md)
- [16:10 ET6 Greenberg Traurig Intellectual Property Attorneys Listed in 2026 IAM Strategy 300](https://longbridge.com/en/news/295703615.md)